BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: A prospective role in resistance to Olaparib

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Dufour, Robin ^a   Daumar, Pierre ^a   Mounetou, Emmanuelle ^b   Aubel, Corinne ^a   Kwiatkowski, Fabrice ^a   Abrial, Catherine ^a   Vatoux, Catherine ^a   Penault Llorca, Frédérique ^a   Bamdad, Mahchid ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; TUMOR PROTEIN;

CARCINOMA; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; METABOLISM; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION;

ANTINEOPLASTIC AGENTS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; TRIPLE NEGATIVE BREAST NEOPLASMS; UP-REGULATION;

EID: 84938633101     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12670     Document Type: Article

References (29)

1. Badve, S. et a. l. Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24, 157-167 (2011).
2. Dawson, S. J. , Provenzano, E. & Caldas, C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 45 Suppl 1, 27-40 (2009).
3. Haupt, B. , Ro, J. Y. & Schwartz, M. R. Basal-like breast carcinoma: A phenotypically distinct entity. Arch Pathol Lab Med 134, 130-133 (2010).
4. D'Andrea, A. D. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med 362, 1909-1919 (2010).
5. Penault-Llorca, F. & Arnould, L. Adjuvant breast cancer: which clinical and pathological characteristics in 2007? Bull Cancer 97, 1421-1426 (2010).
6. Annunziata, C. M. & Bates, S. E. PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer. F1000 Biol Rep 2 (2010), doi: 10. 3410/B2-10.
7. Drew, Y. & Plummer, R. PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat 12, 153-156 (2009).
8. Duffy, M. J. , McGowan, P. M. & Crown, J. Targeted therapy for triple-negative breast cancer: where are we? Int J Cancer 131, 2471-2477 (2012).
9. Hoeijmakers, J. H. DNA damage, aging, and cancer. N Engl J Med 361, 1475-1485 (2009).
10. Tutt, A. & Ashworth, A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 8, 571-576 (2002).
11. Lord, C. J. & Ashworth, A. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 8, 363-369 (2008).
12. ClinicalTrials. gov. A service of the U. S. National Institutes of Health. Available at : https://clinicaltrials. gov/ct2/ results?term= olaparib&pg= 1. (Accessed: 06th May 2015).
13. Bouwman, P. & Jonkers, J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res 20, 540-547 (2014).
14. Kathawala, R. J. , Gupta, P. , Ashby, C. R. , Jr. & Chen, Z. S. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade. Drug Resist Updat 18C, 1-17 (2015).
15. Lord, C. J. & Ashworth, A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 19, 1381-1388 (2013).
16. Rottenberg, S. et a. l. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105, 17079-17084 (2008).
17. Oplustilova, L. et a. l. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 11, 3837-3850 (2012).
18. Valton, E. , Amblard, C. , Wawrzyniak, I. , Penault-Llorca, F. & Bamdad, M. P-gp expression in brown trout erythrocytes: evidence of a detoxification mechanism in fish erythrocytes. Sci Rep 3, 3422 (2013).
19. Sarkadi, B. , Homolya, L. , Szakacs, G. & Varadi, A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86, 1179-1236 (2006).
20. De Laurentiis, M. et a. l. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 36 Suppl 3, S80-S86 (2010).
21. Pal, S. K. & Mortimer, J. Triple-negative breast cancer: novel therapies and new directions. Maturitas 63, 269-274 (2009).
22. Tangutoori, S. , Baldwin, P. & Sridhar, S. PARP inhibitors: A new era of targeted therapy. Maturitas 81(1), 5-9 (2015).
23. Chekhun, V. F. , Zhylchuk, V. E. , Lukyanova, N. Y. , Vorontsova, A. L. & Kudryavets, Y. I. Expression of drug resistance proteins in triple-receptor-negative tumors as the basis of individualized therapy of the breast cancer patients. Exp Oncol 31(2), 123-124 (2009).
24. Samanta, S. , Pursell, B. & Mercurio, A. M. IMP3 protein promotes chemoresistance in breast cancer cells by regulating breast cancer resistance protein (ABCG2) expression. J Biol Chem 288, 12569-12573 (2013).
25. Britton, K. M. et a. l. Breast cancer, side population cells and ABCG2 expression. Cancer Lett 323, 97-105 (2012).
26. Durmus, S. et a. l. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm Res 32, 37-46 (2015).
27. Jaspers, J. E. et a. l. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 3, 68-81 (2013).
28. Lawlor, D. et a. l. PARP Inhibitors as P-glyoprotein Substrates. J Pharm Sci 103, 1913-1920 (2014).
29. Vichai, V. & Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1, 1112-1116 (2006).